Microfluidic array for collecting object in chamber using centrifugal force, object collecting device using microfluidic array, object collecting method using microfluidic array, and method for confirming drug reaction of object using microfluidic array
The microfluidic array addresses cell distribution challenges by employing centrifugal force and porous materials to capture and analyze cells uniformly, enabling efficient quantitative drug screening and precise drug response analysis.
Patent Information
- Application Number
- PCT/KR2026/000752
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-01-13
- Publication Date
- 2026-11-12
AI Technical Summary
Existing methods for capturing and analyzing cells in microfluidic arrays face challenges in uniform distribution, morphological interference, and flow-induced shear stress, particularly for single-cell analysis, necessitating improved cell-loading techniques to minimize these issues and ensure accurate drug response analysis.
A microfluidic array utilizing centrifugal force to separate and collect objects into chambers, featuring a porous material that absorbs gas, ensuring complete fluid filling and uniform cell distribution across chambers, with a rotating device to apply centrifugal force for capturing cells and a method involving fluid injection steps to achieve this.
Enables quantitative drug screening by capturing cells uniformly in chambers using centrifugal force, allowing for simultaneous analysis of drug responses in multiple chambers with minimal interference, facilitating precise drug reactivity verification.
Smart Images

Figure KR2026000752_12112026_PF_FP_ABST
Abstract
Description
A microfluidic array that captures an object in a chamber using centrifugal force, an object capture device using the microfluidic array, a method for capturing an object using the microfluidic array, and a method for confirming a drug reaction of an object using the microfluidic array.
[0001] The present invention relates to a microfluidic array, and more specifically, to a microfluidic array that effectively captures an object in a chamber using centrifugal force.
[0002] Chronic myeloid leukemia (CML) is a blood cancer that accounts for approximately 15% of leukemia cases worldwide. A significant advancement in CML treatment is the development of BCR::ABL1 tyrosine kinase inhibitors (TKIs), which target the underlying molecular abnormalities of the disease and significantly improve patient survival rates. However, in the treatment of complex diseases such as cancer, a "one-size-fits-all" approach that applies equally to all patients has limitations, and treatment responses vary significantly depending on the patient's genetic and biological factors.
[0003] Traditionally, physicians select treatments based on clinical experience, considering the stage of cancer progression and the patient's overall health status. However, if a patient exhibits drug resistance or the risk of recurrence increases due to side effects, treatment must typically be adjusted through trial and error. Consequently, treatment strategies are gradually shifting toward precision personalized medicine that analyzes the patient's individual genetic profile.
[0004] Current genomic sequencing technology helps identify optimal treatments by analyzing the association between a patient's genotype and clinical outcomes, and artificial intelligence (AI), in particular, is more effectively uncovering these correlations in vast amounts of data. While traditional genomic sequencing methods contribute to identifying the molecular characteristics of individual patients, improvements in accuracy, cost-effectiveness, and speed are still needed. Furthermore, clinical outcomes can vary depending on factors such as age, overall health status, personal preferences, and lifestyle. More comprehensive analysis is required to establish a clear association between genetic data and clinical outcomes for specific drugs.
[0005] Direct measurement of drug responses using patient-derived cells can serve as an effective companion diagnostic tool to complementarily analyze a patient's response to specific therapies. However, since patient samples are typically limited, there is a need to develop a platform capable of precisely performing various experiments with even small amounts of cells. In particular, for single-cell analysis, it is necessary to design an array that ensures a uniform cell distribution across hundreds of chambers.
[0006] However, since mammalian cells cannot be effectively guided into a chamber array by diffusion alone, researchers are exploring various cell-loading methods. These methods include vacuum-generated driving forces, gravity, and optical tweezers. Additionally, while various hydrodynamic capture structures are being developed to control cells and surrounding flow within microfluidic channels, further optimization is required to minimize morphological interference and flow-induced shear stress. Furthermore, evenly arranging individual cells on a 2D plane during the process of moving suspended cells captured by these structures into a low-height chamber remains a problem to be solved.
[0007] The present invention aims to provide a microfluidic array that enables quantitative drug screening by effectively capturing a target object in a chamber using centrifugal force.
[0008] According to one aspect of the present invention, the invention provides a microfluidic array comprising a microfluidic channel into which a liquid fluid is introduced and stored, wherein objects having a micro or nano size are dispersed therein and which both ends are closed when storage is completed, and a plurality of chambers spaced apart from each other along the length direction of the microfluidic channel, communicating with the microfluidic channel, and filled with the fluid therein, wherein when a centrifugal force is applied from the microfluidic channel toward the chambers, the objects are separated and collected in each of the chambers by the centrifugal force.
[0009] According to another aspect of the present invention, the invention provides a microfluidic array comprising a microfluidic channel into which a liquid fluid is introduced and a plurality of chambers spaced apart from one another along the longitudinal direction of the microfluidic channel, communicating with the microfluidic channel, and formed of a porous material that partially or entirely absorbs gas, wherein when the liquid fluid introduced into the microfluidic channel flows into each of the chambers, the gas remaining in the chambers is pushed by the liquid fluid and absorbed into each of the chambers, thereby filling the chambers with the liquid fluid.
[0010] According to another aspect of the present invention, the present invention provides an object collection device using a microfluid array, comprising: a microfluid channel into which a liquid fluid is introduced and stored, in which objects having a micro or nano size are dispersed and located within, and which has both ends closed when storage is completed; a microfluid array comprising a plurality of chambers spaced apart from each other along the length direction of the microfluid channel, communicating with the microfluid channel, and filled with the fluid within; and a rotating device on which the microfluid array is mounted and which rotates the microfluid array about a rotation axis formed in the center, wherein when a centrifugal force acts from the microfluid channel toward the chambers by the rotation of the microfluid array, the objects are separated and collected in each of the chambers by the centrifugal force.
[0011] According to another aspect of the present invention, the present invention provides a method for capturing objects using a microfluid array comprising: a microfluid channel into which a liquid fluid, in which objects having a micro or nano size are dispersed and located within it, is introduced and stored, and both ends are closed when storage is completed; and a plurality of chambers spaced apart from each other along the length direction of the microfluid channel, communicating with the microfluid channel, and filled with the fluid within, wherein when a centrifugal force is applied from the microfluid channel toward the chambers, the objects are separated and captured in each of the chambers by the centrifugal force; a first fluid injection step of injecting a first fluid into the microfluid channel to fill the microfluid channel and the chambers with the first fluid; a second fluid injection step of injecting a second fluid, in which the objects are dispersed within it, into the microfluid channel to distribute the objects in the microfluid channel; and an object capture step of causing a centrifugal force to be applied from the microfluid channel toward the chambers so that the objects are introduced into the chambers. Provides
[0012] According to another aspect of the present invention, the present invention comprises the steps of: preparing a microfluid array in which a liquid fluid is introduced and stored, wherein objects having a micro or nano size are dispersed therein, and both ends are closed when storage is completed; and a plurality of chambers spaced apart from one another along the length direction of the microfluid channel, communicating with the microfluid channel, and filled with the fluid therein, wherein when a centrifugal force is applied from the microfluid channel toward the chambers, the objects are separated and collected in each of the chambers by the centrifugal force; a first fluid injection step of injecting a first fluid into the microfluid channel to fill the microfluid channel and the chambers with the first fluid; a second fluid injection step of injecting a second fluid containing the objects into the microfluid channel to distribute the objects in the microfluid channel; and an object collection step of causing a centrifugal force to be applied from the microfluid channel toward the chambers so that the objects are introduced into the chambers, wherein different fluids are introduced into the microfluid array, The present invention provides a method for confirming a drug response of an object using a microfluidic array, comprising: a drug concentration combination step in which at least one of the different fluids is a drug that reacts with the object and mixed fluids are formed by mixing at different mixing ratios; and a test step in which the drug reactivity of the object is confirmed by measuring the change when the object reacts with the mixed fluids.
[0013] A microfluidic array that captures an object in a chamber using centrifugal force according to the present invention, a method for capturing an object using the microfluidic array, and a method for confirming a drug reaction of an object using the microfluidic array have the following effects.
[0014] First, there is an advantage in that quantitative drug screening is possible by using centrifugal force to capture the target object in the chamber.
[0015] Second, it includes multiple branch groups into which mixed fluids of different concentrations formed by different fluids injected through the inlet are each branched and introduced, and each branch group includes multiple chamber groups containing multiple chambers, thereby having the advantage of being able to verify a large amount of drug reactivity at once.
[0016] Third, when centrifugal force is applied, the part of the chamber where the object is placed has a height such that the object cannot be stacked in the vertical direction and can only be placed on the same plane, which has the advantage of making it easy to verify drug responsiveness.
[0017] FIG. 1 is a schematic diagram showing a microfluidic array according to one embodiment of the present invention seated on a holder installed on a rotating device.
[0018] Figure 2 is a schematic diagram showing an overall view of the microfluidic array according to Figure 1 and an enlarged view of the chambers forming a group.
[0019] Figure 3 is a schematic diagram showing how a centrifugal force acts in the direction of the chamber from the main channel of the microfluidic array according to Figure 1, thereby capturing cells in the chamber.
[0020] Figure 4 is a schematic diagram illustrating the process of analyzing drug sensitivity scores using a microfluidic array according to Figure 1.
[0021] Figure 5 is experimental result data regarding the cell growth rate of the chamber for individual and continuous drug treatments using six different tyrosine kinase inhibitors (TKIs) using a microfluidic array according to Figure 1.
[0022] Figure 6 is a graph quantifying and comparing the results of drug sensitivity experiments using a microfluidic array according to Figure 1.
[0023] Figure 7 is a schematic diagram showing automated drug administration and image processing using a microfluidic array according to Figure 1.
[0024] Figure 8 is a schematic diagram showing a cell trapping method in a microfluidic array according to Figure 1 compared with other methods.
[0025] Figure 9 is a schematic diagram showing the preparation process prior to a drug response experiment using a microfluidic array according to Figure 1.
[0026] Figure 10 is a combined image of a tree mixer using fluorescein isothiocyanate (FITC) and sulforodamine B sodium salt (SRB) in a microfluidic array according to Figure 1.
[0027] Figure 11 is an SEM image of the microfluidic array and the fabricated chamber according to Figure 1.
[0028] Figure 12 is the result of a numerical simulation of diffusion-dominant material transport using a microfluidic array according to Figure 1.
[0029] Figure 13 is a photograph showing cell loading using a microfluidic array according to Figure 1.
[0030] FIG. 14 is a schematic diagram showing a rotating device that applies centrifugal force to a microfluidic array according to FIG. 1 and a microfluidic array arranged on the rotating device.
[0031] FIG. 15 is a schematic diagram showing a pneumatic pressure controller used in drug response experiments using a microfluidic array according to FIG. 1.
[0032] Figure 16 is an image processing algorithm for counting live cells using a microfluidic array according to Figure 1.
[0033] Figure 17 is an experimental result showing the difference in the relative number of cells according to the initial number of cells inoculated in a drug response experiment using a microfluidic array according to Figure 1.
[0034] Figure 18 shows the experimental results illustrating the effect of the initial cell inoculation density on the cell response to the drug in a drug response experiment using a microfluidic array according to Figure 1.
[0035] Figure 19 is a histogram showing the initial cell inoculation distribution for each test in a drug response experiment using a microfluidic array according to Figure 1.
[0036] Figure 20 is a graph showing the growth rate curves of three cell lines treated with six tyrosine kinase inhibitors (TKIs) in a drug response experiment using a microfluidic array according to Figure 1.
[0037] Figure 21 is a schematic diagram showing a comparison between a drug screening method using a microfluidic array according to Figure 1 and a conventional drug screening method.
[0038] Figure 22 shows the data used in a drug response experiment using a microfluidic array according to Figure 1.
[0039] Figure 23 shows the TKI and final concentration used in the drug response experiment using the microfluidic array according to Figure 1.
[0040] FIG. 24 is a flowchart illustrating a method for capturing an object using a microfluidic array according to another embodiment of the present invention.
[0041] FIG. 25 is a flowchart illustrating a method for confirming a drug response of an object using a microfluidic array according to another embodiment of the present invention.
[0042] The present invention will be described in detail below by explaining preferred embodiments of the invention with reference to the attached drawings.
[0043] Referring to FIGS. 1 to 23, a microfluidic array (1000) according to one embodiment of the present invention includes an array body (1100), an inlet (1200), a microfluidic channel (1300), a chamber (1400), and an outlet (1500). The array body (1100) is a part that constitutes the exterior (framework) of the microfluidic array (1000). That is, the microfluidic array (1000) has a structure in which the inlet (1200), the microfluidic channel (1300), the chamber (1400), and the outlet (1500) are monolithically formed on the array body (1100). In FIG. 1, only a part of the chamber (1400) and a part of the main channel (1321) constituting the microfluidic channel (1300) are shown in enlarged detail among the microfluidic array (1000).
[0044] Furthermore, the array body (1100) is exemplified as being formed from a polydimethylsiloxane (PDMS) material. This is to ensure that the liquid fluid introduced into the microfluidic channel (1300) can completely fill the chamber (1400). Specifically, when the liquid fluid introduced into the microfluidic channel (1300) flows into the chamber (1400), the gas remaining inside the chamber (1400) is pushed out by the liquid fluid. At this time, if the array body (1100) (chamber (1400)) is formed from a PDMS material, the air inside the array body (1100) (chamber (1400)) is vacuum-suctioned and discharged before the liquid fluid is flowed, thereby forming a porous structure capable of absorbing air within the walls constituting the chamber (1400). Through this, the remaining gas pushed out by the liquid fluid is absorbed into the walls of the chamber (1400). Therefore, since no gas exists inside the chamber (1400), it can be completely filled with a liquid fluid. However, the present invention is not limited thereto, and the material of the array body (1100) can be changed.
[0045] Multiple injection sections (1200) are formed so that different liquid fluids can be introduced. The injection sections (1200) are connected to the microfluidic channel (1300). In this embodiment, two injection sections (1200) are used as examples, but the number of injection sections (1200) can be changed as desired. A first fluid is introduced into the first injection section (1210), which is one of the two injection sections (1200), and a second fluid is injected into the second injection section (1220), which is the other injection section. In this embodiment, the first fluid is a buffer solution and the second fluid is a reagent (drug) as examples, but the types of the first fluid and the second fluid can be changed as desired.
[0046] A microfluidic channel (1300) receives and stores a liquid fluid in which objects having micro or nano sizes are dispersed and located within it. The objects are exemplified as cells for verifying drug responsiveness, but the type of objects can be changed. The microfluidic channel (1300) is exemplified as being formed in a micro size, but the size of the microfluidic channel (1300) can be changed.
[0047] And when the storage of the object and the liquid fluid is completed, both ends of the microfluidic channel (1300) are closed. This is to apply centrifugal force to the objects dispersed in the microfluidic channel (1300) so that the objects flow into the chamber (1400). Therefore, after the objects are captured in the chamber (1400), the microfluidic channel (1300) is opened to inject a drug that reacts with the objects. The two ends refer to the injection part (1200) and the discharge part (1500).
[0048] A plurality of microfluidic channels (1300) are formed such that one end (front end) is connected to each of the injection sections (1200). The other end (rear end) of the microfluidic channel (1300) is connected to the discharge section (1500). Inside the microfluidic channel (1300), fluids flowing from the injection sections (1200) flow and are mixed at different mixing ratios to form different mixed fluids. The mixed fluids are discharged through the discharge section (1500).
[0049] In this embodiment, the microfluidic channel (1300) includes a microfluidic channel front end (1310), a microfluidic channel middle end (1320), and a microfluidic channel rear end (1330). The microfluidic channel front end (1310) has a structure in which one side is connected to each of the injection sections (1200) and is expanded in a multi-stage tree shape. Accordingly, in this embodiment, the concentration of the second fluid increases along the direction from the first injection section (1210) to the second injection section (1220) (opposite direction to the direction in which centrifugal force acts) (a concentration gradient is formed).
[0050] A plurality of microfluidic channel intermediate sections (1320) are formed such that one side is connected to the other side of the microfluidic channel front section (1310). The microfluidic channel intermediate sections (1320) include a main channel (1321) and a bridge channel (1322).
[0051] One side of the main channel (1321) is connected to the microfluidic channel front end (1310), and the other side is connected to the microfluidic channel rear end (1330). The main channel (1321) extends in a direction intersecting the direction in which centrifugal force acts (the longitudinal direction of the array body (1100)). In this embodiment, the part of the main channel (1321) that is connected to the microfluidic channel front end (1310) is divided into a plurality of parts, each of which is spaced apart along the direction in which centrifugal force acts and formed parallel to each other. Although the main channel (1321) is exemplified as being micro-sized, the size of the main channel (1321) can be changed.
[0052] One side of the bridge channel (1322) is in communication with the main channel (1321), and the other side is in communication with the chambers (1400). That is, a plurality of bridge channels (1322) are formed spaced apart along the length of the main channel (1321), which extends from the other side of the microfluidic channel front end (1310) to one side of the microfluidic channel rear end (1330). The bridge channels (1322) are extended parallel to each other in the direction in which centrifugal force acts.
[0053] The bridge channels (1322) are formed in the same number as the chambers (1400). The liquid fluid flowing through the main channel (1321) and the object are introduced into the chamber (1400) through the bridge channels (1322), and the liquid fluid and the object introduced into the chamber (1400) can be discharged back into the main channel (1321) through the bridge channels (1322).
[0054] In this embodiment, the microfluidic channel intermediate section (1320) is exemplified by the portion communicating with the microfluidic channel front section (1310) being divided into nine groups to form branch groups. However, the present invention is not limited thereto, and the number of branch groups can be changed.
[0055] In each of the branch groups included in the microfluidic channel intermediate section (1320), a plurality of chamber groups are formed that are spaced apart along at least one of the longitudinal direction of the microfluidic channel (1300) (the direction intersecting the direction in which centrifugal force acts) and the direction in which centrifugal force acts. In this embodiment, one of the chamber groups includes 25 chambers (1400). And each of the branch groups includes four chamber groups. That is, one branch group includes four chamber groups composed of 25 chambers (1400), so a total of 100 chambers (1400) are included.
[0056] The chambers (1400) included in each of the above chamber groups are arranged to be spaced apart in a direction intersecting the direction in which the centrifugal force acts. And when each of the above chamber groups is composed of a first chamber group to a fourth chamber group, the first chamber group and the second chamber group are arranged to face each other, spaced apart along the direction in which the centrifugal force acts or the direction opposite to the direction in which the centrifugal force acts.
[0057] And the third chamber group and the fourth chamber group are arranged to face each other while spaced apart along the direction in which the centrifugal force acts or the direction opposite to the direction in which the centrifugal force acts. At this time, the third chamber group is spaced apart from the first chamber group in a direction intersecting the direction in which the centrifugal force acts, and the fourth chamber group is spaced apart from the second chamber group in a direction intersecting the direction in which the centrifugal force acts.
[0058] And each of the first to fourth chamber groups is connected in series with the microfluidic channel front section (1310), but has a structure in which the first to fourth chamber groups communicate in parallel with one another. That is, the fluid flowing into the chambers (1400) included in the first to fourth chamber groups flows independently without affecting one another.
[0059] In the microfluidic channel interruption section (1320), when the first fluid is injected into the first injection section (1210) and the second fluid is injected into the second injection section (1220), the concentration of the mixed fluid flowing into each of the branch groups becomes different. However, among the four chamber groups included in each branch group, the concentration of the mixed fluid flowing in is the same.
[0060] Referring to FIG. 3, the portion facing each of the chambers (1400) in the microfluidic channel (1300) (specifically the main channel (1321)) includes a first inclined structure (1321a) and a second inclined structure (1321b). The first inclined structure (1321a) refers to a structure that is inclined in a direction closer to each of the chambers (1400) as it moves toward the imaginary extension lines extending from the center of each of the chambers (1400) to the microfluidic channel (1300), along the direction in which the liquid fluid flows through the microfluidic channel (1300).
[0061] And the second slope structure (1321b) refers to a structure that is sloped away from each of the chambers (1400) as it moves away from the virtual extensions, on the opposite side of the portion where the first slope structure (1321a) is formed around the virtual extensions. The first slope structure (1321a) and the second slope structure (1321b) are formed as symmetric structures with respect to the virtual extensions.
[0062] That is, in this embodiment, the main channel (1321) is not formed in a straight line in the part facing the chambers (1400), but rather has an alternating concave and convex structure. When the main channel (1321) is in communication with the bridge channel (1322), the convex part of the main channel (1321) is positioned in the part facing the chamber (1400), and the concave part of the main channel (1321) is positioned in the part facing the midpoint of adjacent chambers (1400).
[0063] The first slope structure (1321a) and the second slope structure (1321b) are formed from the portion facing the midpoint between one chamber (1400) adjacent to one side of the main channel (1321) to the portion facing the midpoint between another chamber (1400) adjacent to the other side. In this embodiment, the portion of the first slope structure (1321a) and the second slope structure (1321b) formed in the portion facing one chamber (1400) of the main channel (1321) is referred to as the unit volume.
[0064] In this embodiment, at least one of the concentration of the object suspension injected into the microfluidic channel (1300) and the unit volume is adjusted so that an equal number of the objects can be introduced from the main channel (1321) into each chamber (1400). By doing so, each of the unit volumes contains an equal set number of the objects that must be introduced from the main channel (1321) into one chamber (1400).
[0065] The rear end portion (1330) of the microfluidic channel is formed such that one side is connected to the other side of the middle portion (1320) of the microfluidic channel, and has a structure that is multi-stage expanded in an inverted tree shape that is the reverse of the tree shape. The other end portion of the microfluidic channel rear end portion (1330) is connected to the discharge portions (1500) respectively.
[0066] The chambers (1400) are spaced apart from each other along the longitudinal direction of the microfluidic channel (1300) (a direction intersecting the direction in which centrifugal force acts). The chambers (1400) are connected to the microfluidic channel (1300). Specifically, the chambers (1400) are connected to the bridge channel (1322) among the intermediate sections (1320) of the microfluidic channel. The chambers (1400) are filled with the fluid inside and are spaced apart from each other. When a centrifugal force acts from the microfluidic channel (1300) toward the chambers (1400), the objects are separated and collected into the chambers (1400) by the centrifugal force.
[0067] The chamber (1400) has a plurality of chamber spaces that are interconnected. The plurality of chamber spaces are formed in a structure such that the height at which the object can pass decreases in the interconnected portions as the centrifugal force acts in the direction in which it is applied.
[0068] In this embodiment, the chamber (1400) has a first chamber space (1400a) and a second chamber space (1400b). However, the present invention is not limited thereto and may have three or more chamber spaces. The first chamber space (1400a) is one of the chamber spaces, and one side is in communication with a microfluidic channel (1300) (specifically, a bridge channel (1322)). The second chamber space (1400b) is another of the chamber spaces, and one side is in communication with the other side of the first chamber space (1400a).
[0069] The second chamber space (1400b) is formed with a vertical height such that a single object can be placed. This is intended to ensure that the objects are not stacked in the second chamber space (1400b), as it is difficult to visually confirm the reactivity of the objects when the objects are stacked vertically when the objects are introduced into the second chamber space (1400b) by centrifugal force. However, the present invention is not limited thereto, and the second chamber space (1400b) may be formed with a vertical height that is higher than the height at which a single object can be placed, but lower than the height at which two objects can be stacked vertically.
[0070] And the chamber (1400) is positioned such that the second chamber space (1400b) is positioned above the first chamber space (1400a). This is because the microfluidic array (1000) is positioned at an angle. Specifically, the microfluidic array (1000) has the chambers (1400) positioned above the microfluidic channel (1300). Specifically, the chambers (1400) are positioned above the part of the main channel (1321) that faces the chamber (1400) and above the bridge channel (1322). This is to ensure that when the centrifugal force is removed while the objects are being introduced into the chamber (1400) through the application of centrifugal force, the objects can be automatically discharged from the chamber (1400) toward the main channel (1321) by gravity.
[0071] Hereinafter, a rotating device (2000) that provides centrifugal force (FC) to a microfluidic array (1000) is briefly described. A device in which a microfluidic array (1000) is mounted on a rotating device (2000) is referred to as an object collection device using a microfluidic array.
[0072] The rotating device (2000) includes a base (2100), a holder (2200), an inclined plate (2300), and a control device (not shown). A rotating shaft (2100a) is formed in the center of the base (2100) and protrudes therefrom, which is capable of rotating in place in the up and down direction.
[0073] The holder (2200) is coupled to a rotation axis (2100a) whose center protrudes from the base (2100). The holder (2200) extends radially away from the center, and when the rotation axis (2100a) rotates, the radially extended portion rotates with the rotation axis (2100a) as the central axis. The holder (2200) has an inclined structure formed on the radially extended portion.
[0074] Specifically, the holder (2200) includes a holder body (2210), a first guide part (2220), and a second guide part (2230). The holder body (2210) extends flatly in the radial direction from the portion connected to the rotation axis (2100a).
[0075] The first guide part (2220) has a plate shape and is coupled to the radial end of the holder body (2210). The first guide part (2220) extends downward from one end of the holder body (2210) in a direction intersecting the radial direction. The second guide part (2230) has a plate shape and is coupled to the radial end of the holder body (2210). The second guide part (2230) extends downward from the other end of the holder body (2210), which is opposite to the end of the direction intersecting the radial direction.
[0076] The inclined plate (2300) has a rectangular plate shape. A microfluid array (1000) is fixedly positioned on the upper part of the inclined plate (2300). The inclined plate (2300) is attached to the end to which the holder body (2210) is extended in a detachable structure. Specifically, one end of the inclined plate (2300) in the direction intersecting the radial direction is coupled to the inner side where the first guide part (2220) faces the second guide part (2230), and the other end of the direction intersecting the radial direction is coupled to the inner side where the second guide part (2230) faces the first guide part (2220).
[0077] The inclined plate (2300) is positioned at an angle such that its height increases from the closer side to the farther side with respect to a virtual axis extending the rotation axis (2100a) in the vertical direction. At this time, since the chamber (1400) is positioned at the farther side and the main channel (1321) is positioned at the closer side, the chamber (1400) is positioned higher than the main channel (1321).
[0078] The control device is connected to the inclined plate (2300) via a wired or wireless network. The control device can adjust the inclined angle of the inclined plate (2300) by rotating the part of the inclined plate (2300) that is combined with the first guide part (2220) and the second guide part (2230).
[0079] In this embodiment, the holder (2200) and the inclined plate (2300) are exemplified as being formed in pairs so as to be symmetrical around the rotation axis (2100a). However, the present invention is not limited thereto, and the number of holders (2200) and inclined plates (2300) can be changed.
[0080] Hereinafter, a method for capturing an object using a microfluidic array will be described with reference to FIGS. 1 to 24.
[0081] Referring to FIG. 24, a method for capturing an object using a microfluidic array according to another embodiment of the present invention (S100) includes a step of preparing a microfluidic array (S110), a first fluid injection step (S120), a second fluid injection step (S130), and a step of capturing an object (S140). The step of preparing a microfluidic array (S110) is a process of preparing a microfluidic array (1000) according to FIGS. 1 to 23. In the step of preparing a microfluidic array (S110), the microfluidic array (1000) is formed from a PDMS material.
[0082] The first fluid injection step (S120) is a process of injecting the first fluid into the microfluidic channel (1300) to fill the microfluidic channel (1300) and the chamber (1400) with the first fluid. In this embodiment, the first fluid is a buffer solution. Additionally, although not shown in the drawings, a vacuum formation step is included prior to the first fluid preparation step (S120).
[0083] In the vacuum formation step, air inside the microfluidic channels (1300) and chambers (1400) of the microfluidic array (1000) is vacuum-suctioned and discharged from the microfluidic array (1000). Through this, a porous structure capable of absorbing air is formed inside the walls constituting the chambers (1400). This is to ensure that the first fluid injected in the first fluid injection step (S120) can completely fill the chamber (1400). That is, when a porous structure is formed on the walls of the chamber (1400) by the vacuum formation step, even if there is residual gas inside the chamber (1400) due to the first fluid, the residual gas is pushed and absorbed by the walls of the chamber (1400) by the first fluid flowing into the chamber (1400), so that no remaining gas is left, thereby allowing the first fluid to completely fill the chamber (1400).
[0084] The second fluid injection step (S130) is a process of distributing a second fluid, in which objects requiring verification of reactivity to a reagent (drug) are dispersed, into a microfluidic channel (1300). In this embodiment, the objects are exemplified as cells, but the type of objects can be changed. That is, the second fluid is a cell suspension. The cell suspension is injected through the discharge section (1500). Depending on the concentration of the injected cell suspension, the cells are uniformly distributed within the main channel (1321).
[0085] The object collection step (S140) is a process of causing centrifugal force to act from the microfluidic channel (1300) toward the chambers (1400) so that the objects are introduced into the chambers (1400). That is, in the object collection step (S140), while the microfluidic array (1000) is seated on the inclined plate (2300) of the rotating device (2000), the rotation axis (2100a) is rotated to generate centrifugal force from the main channel (1321) toward the chambers (1400), thereby causing the objects dispersed in the main channel (1321) to be introduced into each of the chambers (1400).
[0086] Hereinafter, a method for confirming the drug response of an object using a microfluidic array is described with reference to FIGS. 1 to 23 and 25.
[0087] Referring to FIG. 25, a method for confirming a drug response of an object using a microfluidic array according to another embodiment of the present invention (S200) includes a step of preparing a microfluidic array (S210), a first fluid injection step (S220), a second fluid injection step (S230), an object capture step (S240), a drug concentration combination step (S250), and a test step (S260). Since the first fluid injection step (S220) and the object capture step (S240) are similar to the object capture method (S100) using a microfluidic array of FIG. 24, a detailed description is omitted.
[0088] In the step (S210) of preparing a microfluidic array, each of the chamber groups prepares a microfluidic array (1000) comprising a plurality of chambers (1400). At this time, a fluid of the same concentration containing a drug is introduced into the plurality of chambers (1400) included in each of the chamber groups, and a fluid of a different concentration containing a drug is introduced between the different chamber groups (1400).
[0089] The second fluid injection step (S230) is generally similar to the second fluid injection step (S130) of FIG. 24, but has some differences. The difference is that, in order to visually confirm the drug reactivity of the object, a second fluid containing a fluorescent protein that changes according to the type and concentration of the drug is injected into a microfluidic channel (1300) in which the object is dispersed.
[0090] The drug concentration mixing step (S250) is a process of introducing mixed fluids, mixed at different mixing ratios, into each of the chambers (1400). In the drug concentration mixing step (S250), different fluids are injected into the first injection port (1210) and the second injection port (1220) of the microfluidic array (1000). At this time, at least one of the different fluids is a reagent (drug) that reacts with the target object. That is, a buffer solution is injected into the first injection port (1210), and a reagent is injected into the second injection port (1220).
[0091] In this embodiment, the step of injecting a third fluid into the microfluidic channel (1300) is further included prior to the drug concentration combination step (S250). The third fluid is exemplified as a buffer solution, but the type of the third fluid can be changed. This is to ensure that the microfluidic channel (1300) is kept clean by effectively removing residual substances (cells) present in the microfluidic channel (1300) through the injection of a clean fluid into the microfluidic channel (1300). Through this, experimental accuracy can be improved when confirming drug responsiveness. FIG. 9 illustrates the sequential wetting process occurring in the chamber (1400).
[0092] The test step (S260) is a process of confirming the drug reactivity of the object by measuring the change when the object reacts with the mixed fluids. In the test step (S260), the reactivity of the object according to the concentration of the drug is confirmed by using the number of times the object reacts with the drug in the chamber (1400) included in each of the chamber groups.
[0093] Figure 2(a) is a photograph of a microfluidic device consisting of a Christmas tree-shaped mixer (black dashed box) for generating a concentration gradient and a culture chamber array with 900 chambers (red dashed box). (b) is a fluorescence image of the mixer created by merging two fluorescence images obtained using fluorescein isothiocyanate and sulforodamine B sodium salt. Nine distinct concentrations are formed linearly along the mixer in ascending order from two media and drug inlets, numbered #1 to #9. (c) shows that each concentration line contains 100 chambers, divided into four subgroups of 25 chambers each to minimize the influence of upstream chambers on downstream chambers. (d) is a numerical simulation showing the convective flow velocities within the channels and chambers.
[0094] Figure 3(a) is a diagram of the cell loading and transfer process (scale bar: 100 μm). (b) is a microscopic image of the two-stage compartmentalization process. Cells are loaded by pipetting and then transferred to the chamber by centrifugal force (ii), indicated by the yellow arrow (i) (scale bar: 200 μm). (c) shows the controllability and distribution of the number of compartmentalized cells. The left panel shows a histogram of the number of cells between compartments, and the right panel shows a fitted Gaussian distribution with mean ± standard deviation (SD).
[0095] Figure 4 shows the results of automated image acquisition and processing for drug susceptibility score analysis. A is a representative brightfield image and endpoint apoptosis staining image at t = 0, 24, and 48 hours. The first row shows the row numbers (#1–#9), and the second row lists the corresponding drug concentrations generated linearly and sequentially in the microfluidic array. B is a computerized image processing workflow for the captured brightfield images (t = 0, 24, and 48 hours) and endpoint apoptosis staining image (t = 48 hours).
[0096] Figure 5A is a heatmap showing normalized growth rates under nine concentration conditions for each of the six tyrosine kinase inhibitors (TKIs). Each column represents 25 chambers, and four sets of columns represent identical culture conditions, corresponding to 100 chambers per concentration in a single microfluidic array. Each row shows cell growth rates according to the concentration gradient of the nine concentrations. The top and bottom rows correspond to the upstream and downstream chambers. Figure 5B is a graph of normalized cell growth rates according to various drug concentrations for the six TKIs. This allows for the analysis of the effect of the initial cell inoculation number on growth rate.
[0097] Figure 6 (A) shows the proliferation rate calculated from cell counting data and graphed against concentration. (B) is the normalized growth curve, and (C) is the relative inhibition rate used to compare drug sensitivity scores. (D) is a schematic representation of the drug sensitivity score, representing the relative efficacy of the tested drugs calculated using various sensitivity scoring methods. (EG) is a comparison graph of the semi-maximum inhibition concentration (IC50), growth rate inhibition (GR50), Emax, Hill coefficient, and drug sensitivity score (DSS) values for K562, Ba / F3, and Ba / F3 T315I. It is a radar chart showing drug sensitivity on a logarithmic scale, providing visual guidance for personalized drug selection and treatment.
[0098] Figure 9 (A) illustrates the workflow of the microfluidic array. The microfluidic array is sterilized in an autoclave prior to the experiment to protect it from external contaminants. (i) In the initial stage, the microfluidic array fills the channels and chambers with the medium through channel wetting using a vacuum. This process ensures that the microfluidic array is uniformly filled with the medium. (ii) A cell suspension is injected through the outlet to load the cells into the channels. Depending on the concentration of the injected cell suspension, the cells are uniformly distributed within the channels. (iii) The cells are compartmentalized into the chamber. Centrifugation is applied to achieve effective delivery, stably transporting the cells into the chamber. (iv) Clean medium is injected to effectively remove residual cells from the channels, keeping them clean and providing optimal conditions for the experiment. Once the microfluidic array is ready, the medium or drug is connected to the inlet to proceed with the experiment. (B) is an image showing the sequential wetting process in the chamber.
[0099] Figure 10A shows a merged image of a tree mixer at the front of a microfluidic channel being measured using flufluorescein isothiocyanate (FITC) and sulforodamine B sodium salt (SRB). The red box image shows that the fluorescent molecules are completely mixed while passing through the mixer channel. Figure 10B shows a graph of the normalized fluorescence intensity of FITC under various flow rate conditions. Figure 10C shows a graph of the fluorescence intensity in the chamber as the stepwise FITC solution is supplied and diffused into the chamber through the microfluidic channel.
[0100] (A) of Fig. 12 is a simulation result showing the average convective velocity in the chamber. The red dashed circle indicates the condition where the Peclet number (Pe) is in the range of 0.1 to 0.001. (B) shows the heat map of the fluid velocity in the steady state. The white line indicates the streamline. The red dashed box indicates the condition where Pe is in the range of 0.1 to 0.001. (C) shows the simulation result of the normalized target molecule concentration in the chamber. Within about 15 minutes, all material in the chamber is completely exchanged by diffusion. (D) is a simulation result of diffusion-induced chamber regeneration.
[0101] Figure 13 (A) shows a photograph of cell loading. The cell suspension is loaded into the main channel (1321) via pipetting (left). For more stable cell loading, a syringe pump can be used to introduce cells through a constricted flow (right). The cell suspension is injected through the outlet at a low flow rate to ensure uniform loading, after which waste can be removed through the outlet. The hydrodynamic resistance of the microfluidic array is adjusted to allow uniform pipetting at a sufficiently low flow rate, enabling uniform loading without additional equipment. Additionally, connecting a syringe to the fluid or drug inlet creates a constricted flow to further stabilize cell loading. (B) shows a microscopic image of cells loaded into the main channel. The red dashed box indicates the unit volume. The scale bar is 200 µm. In (C), the reproducibility of cell delivery shows high uniformity, with an average of 5.14 cells (SD ± 0.48) across five separate cell deliveries.
[0102] Figure 14 (A) is a schematic diagram of a centrifugal cell delivery setup using a microfluidic array. The chamber is assembled so as to face outward from the axis of rotation and attached to an inclined plate. (B) is an image of a holder mounted on the axis of rotation. The holder is fabricated using 3D printing and laser cutting. The distance from the axis of rotation to the center of the microfluidic array is 15 cm. (C) is an image showing cells remaining suspended in the middle because they are not fully loaded at the bottom of the chamber due to insufficient RPM. When the rotation exceeds 600 RPM, sufficient centrifugal force is applied, effectively delivering cells from the main channel to the bottom of the chamber. (D) shows a comparison of the efficiency of cell delivery at various rotation speeds and times of the rotating device.
[0103] Figure 15 (A) shows the design and operation of the electrical and fluid circuits. The controller controls eight devices in series through a single graphical user interface by sharing commands via RS485 communication. (B) shows the tubing between the graphical user interface (left), the custom-developed electrical circuit board (center), and the microfluidic array and pneumatic pressure controller (right).
[0104] Figure 16A shows the cell counting results obtained from four chambers using a MATLAB algorithm to detect cell boundaries. Figure 16B represents the counting accuracy according to the number of cells in each chamber. The number of cells counted by the algorithm is compared with the number of cells counted manually. The R² value in Figure 16C represents the correlation between manual and algorithm-based cell counting.
[0105] Figure 17 graphs the difference in relative cell counts for all 18 test sets using K562 cells and classifies them into groups of 0–5, 5–10, 10–15, 15–20, and 20–25 cells. Error bars represent the mean ± standard deviation (SD).
[0106] In Figure 18, the drug response is analyzed based on the initial number of cells inoculated into the chamber. The results are selected randomly. An average of 10 cells are inoculated per chamber, but since the inoculation follows a Gaussian distribution, chambers with varying cell numbers can be monitored. The analysis is subdivided into groups of 0-5, 5-10, 10-15, 15-20, and 20-25 cells. Most chambers show similar drug responses, but deviations from the mean are observed when the number of cells is less than 5 or more than 20.
[0107] In Fig. 19, the histogram shows the initial cell number distribution of the entire experimental chamber corresponding to the data in Fig. 18. The cell number groups (0-5, 5-10, 10-15, 15-20, 20-25) are distinctly color-coded to enhance clarity.
[0108] Figure 20 shows the growth curves of three cell lines treated with six tyrosine kinase inhibitors (TKIs). A is the K562, B is the Ba / F3, and C is the Ba / F3 T315I mutant. The data are converted into growth rate (GR) curves. Error bars represent the mean ± standard deviation (SD). All experiments were performed as biological replicates (n ≥ 2).
[0109] Figure 21 illustrates a comparison between microfluidic high-throughput drug screening for personalized drug therapy and conventional methods. A represents a conventional single-size-all drug selection method based on empirical observations of patients. B represents the proposed single-cell level and high-throughput drug screening and diagnostic method. This consists of a microfluidic compartmentalized chamber array for cell culture and drug transport, and an image acquisition and processing module for analyzing drug-cell interactions and quantifying cell viability in response to various anticancer agents. Comparing the relative drug sensitivities of multiple drug candidates demonstrates high potential for personalized precision therapy.
[0110] Below, details regarding experiments using a microfluidic array (1000) are described.
[0111] 1. Overview
[0112] We propose a customized drug screening approach and, for this purpose, develop a system that monitors the drug response of cancer cells while controlling drug type and concentration by combining a microfluidic cell culture array device and an external pneumatic pressure control system (Fig. 21(B(i)).
[0113] The proposed microfluidic device compartmentalizes target cells in 900 culture chambers and generates nine different drug concentrations using a Christmas tree-like mixer. Cells are loaded into the device and moved to a dead-end chamber array using centrifugal forces, which enables 2D imaging at the single-cell level. Additionally, an image processing algorithm is developed to quantitatively analyze cell-drug interactions, which can be used to compare the effects of multiple candidate drugs (Fig. 21B (ii-iv)).
[0114] To verify the practicality of this approach, a comparative analysis is performed on six BCR::ABL1 tyrosine kinase inhibitors (TKIs) (imatinib, nilotinib, bosutinib, ponatinib, dasatinib, and asiminib). The experiment uses K562 CML cell lines and Ba / F3 cell lines expressing BCR-ABL1 and BCR-ABL1 T315I mutations. In particular, BCR-ABL1 T315I mutant cell lines exhibit resistance to first- and second-generation TKIs, making them an important model for precisely evaluating the efficacy of the treatments.
[0115] Based on the analysis results, key physiological indicators such as the IC50, growth rate inhibition value (GR50), and drug sensitivity score (DSS) are calculated. These indicators are used to quantitatively compare cellular drug sensitivity on a microfluidic chip and provide a useful data basis for establishing personalized treatment strategies (Fig. 21B (v-vi)).
[0116] 2. Materials and Methods
[0117] 2.1. Anticancer Agents and Reagents
[0118] Six BCR-ABL1 inhibitors (TKIs) are used as targeted therapies for BCR-ABL tyrosine kinases. Representative drugs include imatinib mesylate (IM; SML1027), nilotinib (NI; SML3799), bosutinib (BO; HY-10158, MedChemExpress), dasatinib (DA; C2354, Cellagen Tech.), ponatinib (PO; HY-12047, MedChemExpress), and asiminib (AS; HY-104010, MedChemExpress).
[0119] Each BCR-ABL1 TKI was prepared as a stock solution by dissolving it in dimethyl sulfoxide (DMSO), and detailed information regarding this is presented in Fig. 23. To minimize the potential effects of DMSO, the final DMSO concentration was maintained at less than 0.1% in all experiments. Additionally, the final concentrations of the drugs used in the experiments are also described in detail in Fig. 23, and all drugs are stored in a -70°C ultra-low temperature freezer.
[0120] In addition, fluorescent substances FITC (fluorescein isothiocyanate; F7250) and sulforodamine B sodium salt (SRB; S1402) are diluted in 1X phosphate-buffered saline (PBS; P54593) and used to characterize the concentration gradient generator and diffusion time.
[0121] 2.2. Cell Culture
[0122] Human chronic myeloid leukemia (CML) cell line K562 is obtained from ATCC (CCL-243; Manassas, VA, USA) and cultured. RPMI 1640 medium (SH30027; Cytiva) is used for culture, supplemented with 10% fetal serum (FBS; TMS-013-BKR, Specialty media) and 1% penicillin-streptomycin (15240062; Gibco). K562 cells are cultured in a CO₂ incubator (MCO-170AIC; PHC Corp.) at 37°C, 5% CO₂, and a relative humidity of 95% or higher.
[0123] When the cell density reaches approximately 5.0 × 10⁴ cells / mL, subculture to 5.0 × 10⁴ cells / mL in warm fresh medium. K562 cells are subcultured in T75 culture flasks every 2 to 3 days to maintain the exponential growth phase, and the cells are managed for 15 passages or fewer.
[0124] 2.3. Device Fabrication
[0125] The microfluidic device is fabricated using conventional photolithography and soft lithography techniques. First, a master mold is fabricated through a two-step photolithography process using negative photoresist (SU-8 3025, Microchem), thereby forming a bilayer structure. The first layer consists of a cell culture chamber with a height of 20 µm, and the second layer contains a microchannel with a height of 50 µm for fluid flow. The height of the fabricated structure is verified using a surface profiler (P-6, KLA Tencor).
[0126] Next, the fabricated master mold is passedivated by vapor deposition of perfluorosilane (PFOCTS; Trichloro(1H,1H,2H,2H-perfluorooctyl)silane, Sigma) before the flexible lithography process. Subsequently, polydimethylsiloxane (PDMS; Sylgard 184, Dow Corning) is mixed with a curing agent in a 10:1 ratio to proceed with the lithography process. The thickness of the PDMS layer is adjusted to approximately 8 mm to ensure optimal CO₂ diffusion.
[0127] To mitigate the problem of PDMS absorbing hydrophobic small molecule compounds, the PDMS surface is coated by direct covalent bonding with 0.1 M polyethylene glycol silane (PEG silane; AB111226, abcr GmbH). The PEG-coated surface also serves to minimize non-specific interactions with drug molecules and cells.
[0128] Finally, the PDMS chip and glass slide (76 × 52 mm², Matsunami) are irreversibly combined for 1 minute at 70 W and 0.3 mbar conditions via O₂ plasma treatment (CUTE, Femtoscience). The fabricated microfluidic device is sterilized in an autoclave prior to the experiment to prevent contamination. Afterward, the device is degassed in a vacuum chamber, the device is moistened with culture medium to compartmentalize the cells, and then the medium is exchanged to proceed with the culture process (Fig. 9).
[0129] 2.4. Experiment Setup and Data Analysis
[0130] Bright-field and fluorescence images are acquired using an sCMOS camera (SONA, Andor Technology Ltd.) mounted on an inverted fluorescence microscope (ECLIPSE Ti2-E, Nikon). The microscope features a fully automated motor-driven stage and uses a light source combining an LED lamp and a fluorescent LED. The operation of the microscope is controlled via NIS-Elements AR software.
[0131] Each cell culture chamber is imaged using a 10x magnification objective lens, and fluorescence intensity is quantified using ImageJ software (National Institutes of Health). Scanning electron microscopy (SEM) images are acquired using a cold-cathode field-emission scanning electron microscope (SU8220, Hitachi). Analysis and visualization of experimental data are performed using ImageJ (National Institutes of Health, Bethesda, MD, USA), OriginPro 2020 (OriginLab Corp., Northampton, MA, USA), MATLAB R2023b (Mathworks, Inc., Natick, MA, USA), and Python (version 3.12.2). A detailed description of the experimental setup for image acquisition can be found in the Supplementary Notes (Section A).
[0132] 3. Results
[0133] 3.1. Design and Operating Principles of Microfluidic Devices for Cell Culture and Concentration Gradients
[0134] Figure 2(a) shows the arrangement of the concentration gradient generator (Christmas tree-mixer) and the cell culture chamber, which are the two main components of the microfluidic device. The drug (1X) and the culture medium are injected into the microfluidic tree-mixer through their respective inlets, thereby setting the concentration of the drug delivered to the cell culture chamber to the following nine stepwise concentrations: 0X, 0.125X, 0.25X, 0.375X, 0.5X, 0.625X, 0.75X, 0.875X, 1X.
[0135] This tree mixer manually forms a concentration gradient to reduce reagent waste and minimize errors that may occur in manual serial dilution. The profile of the formed concentration gradient is quantitatively evaluated by injecting FITC and SRB, and each concentration condition corresponds to line numbers #1 through #9 (Fig. 2(b)).
[0136] A stable concentration gradient is formed when the flow rate of each reagent is 4 μL / min or less, and then diffuses into the cell culture chamber (Figures S3A-B). The dynamic process of the 9-step concentration diffusing into the chamber was measured through changes in fluorescence intensity, and it was confirmed that a steady state was reached after about 30 minutes (Figures 1 and 3).
[0137] As can be seen in Fig. 2(c), each concentration gradient generated in the upstream mixer branches into four identical subgroups (gray) and maintains chemical equilibrium in the cell culture chamber (blue). The height of the tree mixer and the main channel (50 μm) is designed to deliver sufficient nutrients to each culture chamber.
[0138] The overall layout of the microfluidic device and the chamber and channel design are shown in Fig. 11. The device contains a total of 900 cell chambers, with 100 chambers allocated for each concentration condition. When multiple chambers are connected in series, there is a possibility that growth factors generated in the upstream chambers may affect the cells in the downstream chambers. To prevent this, the 100 chambers are divided into four parallel groups of 25 to minimize mutual interference and prevent back-diffusion of growth factors (Fig. 11B).
[0139] Each cell chamber is 20 μm high, has a dead-end structure, and is connected to the main channel through a bridge channel (Fig. 11 CD). Considering that the size of the cells used in the experiment is approximately 20 μm, the chamber size is designed to enable single-layer cell growth, thereby preventing cell overlap and improving optical imaging at the single-cell level.
[0140] In addition, numerical simulations are performed to optimize the channel size in order to minimize abnormal cell responses caused by shear stress generated by the flow (Fig. 2(d)). This allows for rapid fluid exchange while minimizing shear stress within the cell culture chamber. Under optimized conditions, the Peclet number is maintained between 0.001 and 0.1.
[0141] Detailed numerical simulation results are provided in Fig. 12. According to the simulation results, through the optimized channel design, material exchange from the main channel to the chamber is effectively achieved within 15 minutes via diffusion. This reduces cell death caused by nutrient deficiency and efficiently removes metabolites secreted by cells, thereby creating a stable culture environment.
[0142] 3.2. Two-stage cell compartmentalization by centrifugal force
[0143] Cells are loaded into a low-height chamber array in the main channel by applying a two-stage cell compartmentalization method utilizing centrifugal force (Fig. 3).
[0144] In the first step, a cell suspension is injected through the outlet of the microfluidic device. The injected cells are distributed along the microchannels, allowing for precise control of the number of cells captured per unit volume by adjusting the concentration of the cell suspension (red dashed box in (a)(i) of Fig. 3).
[0145] For example, when a cell suspension of 1 × 10⁶ cells / mL is injected into the channel, on average, about 5 cells are captured per volume of 5 nL (500 × 200 × 50 µm³, L×W×H), with a standard deviation of ±0.48. This process is confirmed through experimental verification, and the results are presented in Figures 13 B and C.
[0146] The second step involves moving cells uniformly distributed within a unit volume to an adjacent dead-end chamber, using a zigzag-shaped structure to move the cells by centrifugal force (Fig. 3(a)(ii)). During this process, the microfluidic device is fixed to a 3D-printed poly(methyl methacrylate), PMMA jig and then rotated using a commercial centrifuge (Fig. 1). To apply uniform centrifugal force within the cell chamber and minimize the effects of distance changes, the device is positioned 15 cm away from the center of rotation and mounted at a 35° tilt to prevent cell blockage by the channel walls (Fig. 14 A and B). This design helps to resolve the problem of cell obstruction that may occur due to the height difference between the main channel (50 µm) and the chamber (20-25 µm). While applying centrifugal force, the relative centrifugal force (RCF) is maintained at a lower level than that used for cell spin-down in general biological experiments to minimize stress on the cells.
[0147] Through this, cells are effectively moved to the bottom of the chamber, and the results are shown in Fig. 3. In addition, to establish optimal cell movement conditions, RCF values were compared at various revolutions per minute (RPM), and the cell capture results were analyzed (Fig. 14 C and D). Based on this, the RPM range capable of effectively capturing cells was set to 600–800 RPM. In subsequent experiments, cells were compartmentalized in the chamber by rotating at 600 RPM for 3 minutes. Fig. 3 (c) shows the relationship between the concentration of the injected cell suspension and the number of cells captured in the chamber, which follows a Gaussian distribution. Generally, dead-end chamber structures have the disadvantage of making cell capture difficult due to the lack of fluid flow; however, the cell capture method using centrifugal force proposed in this study serves as an effective technique that overcomes these limitations while reducing unnecessary shear stress.
[0148] 3.3. Cell Culture and Live Cell Counting via Image Processing
[0149] Figure 4 shows the image processing workflow for counting live cells and cell culture images in a microfluidic chamber array. First, an average of 10 cells per chamber are compartmentalized, and culture is carried out under drug-free continuous culture conditions (flow rate approximately 4 µL / min). Medium and drugs are supplied to the microfluidic device via a pneumatic pressure control unit, which is designed to operate up to 64 valves simultaneously (Figure 15). Up to eight panels can be controlled using a single graphical user interface (GUI), with each panel managing eight valves to enable high-throughput and parallel experiment execution. After cell seeding, the drug treatment protocol is initiated. The number of cells at the beginning of the experiment (t = 0 h, t0) is used as a reference value in Figure 4. Subsequently, cells were exposed to nine different drug concentrations (e.g., imatinib) for 48 hours, and imaging was performed at 24-hour intervals (t1 = 24h; t2 = 48h). Experimental results showed that cells in the chamber connected to line #1 (no drug, control) proliferated normally, whereas cells in the chamber connected to line #9 (highest concentration of drug) exhibited apoptosis due to the anticancer drug effect. Finally, apoptosis was further confirmed via Annexin V-FITC / PI staining. This staining method detects dead cells based on fluorescent signals; Annexin V-FITC stains phosphatidylserine exposed on the outer surface of the cell membrane to indicate early apoptosis, while PI (propium iodide) stains intracellular DNA with damaged membranes to indicate late apoptosis or necrosis.Through this analysis, it can be demonstrated that cell viability at various drug concentrations can be quantitatively evaluated in microfluidic devices.
[0150] Figure 4B illustrates the image processing workflow, utilizing a proprietary MATLAB algorithm to count viable cells. Bright-field images of each chamber are cropped, and the chamber walls and cell boundaries are segmented and analyzed. To exclude the effects of apoptosis, dead cells are excluded by utilizing apoptosis staining results based on the characteristics of viable cells. This algorithm provides more accurate viable cell counting by eliminating errors that may arise from image defects or noise. To evaluate the accuracy of the algorithm, a comparative analysis is performed with results obtained by manual counting by experienced researchers. As shown in Figure 16, the accuracy of the algorithm increases with the cell count, demonstrating that the total number of cells directly influences precision. Overall, the algorithm achieved an average accuracy of 94.7%, confirming that it meets the level of precision required for this study.
[0151] 3.4. Analysis of Cell Responses to Six TKIs
[0152] After culturing the K562 cell line on a microfluidic chip, six types of BCR-ABL1 TKIs ranging from the first to fourth generations were applied. Detailed information regarding the drugs is provided in Fig. 22. Fig. 5A shows the heatmap results representing the relative cell count (compared to the initial cell count at t0 = 0 hours) after t2 = 48 hours under nine different drug concentration conditions. Each column consists of 25 chambers, and since four columns have identical culture conditions, a total of 100 chambers per concentration condition are analyzed on a single chip. Additionally, within each column, the chambers are arranged from the upstream (top) to the downstream (bottom) direction. The heatmap results confirm a pattern in which cell proliferation gradually decreases as the concentration increases for all TKIs (Fig. 4A). Notably, no significant difference was observed between the upstream and downstream regions within the column, suggesting that the culture environment is maintained uniformly through the continuous supply of fresh nutrients. This demonstrates that consistent cell proliferation occurs in a culture environment similar to a chemostat maintained by a pressure control system. Additionally, it is confirmed that cross-interference between adjacent chambers with different concentration conditions is minimized as sufficient spacing is maintained between chambers. The drug concentration range is carefully determined by referring to existing literature (Fig. 22), and is adjusted to maintain a drug concentration near IC50, specifically by setting the rate of change in cell number in the central column (Line #5) to be close to approximately 0.5.
[0153] Heatmap analysis results demonstrate that the microfluidic chamber array can effectively visualize the effect of anticancer drugs on cell viability. Variability between chambers is observed even within the same drug concentration, which is interpreted as being due to differing drug sensitivities resulting from cellular heterogeneity and differences in cell cycle stages. Additionally, the initial cell seeding number can also influence this variability. For example, in chambers seeded with fewer than 5 cells (< 5) or more than 20 cells (> 20), a tendency for decreased cell proliferation was observed even in the control line (Fig. 17). In particular, in chambers seeded with fewer than 3 initial cells (< 3), there is a higher likelihood of errors during the cell counting process, which may result in slight differences in proliferation rates compared to adjacent chambers. These differences are represented by white segments in the heatmap, reflecting missing values.
[0154] Next, the average response curves (n = 3) for the six TKIs were analyzed at various concentrations and expressed as the relative number of cells at t2 (t2 / t0) (Fig. 5B). To maintain experimental consistency, data from chambers with an initial cell count of less than 3 (< 3) or greater than 17 (> 17) were excluded. The average initial cell count was 10, and 81.7% of all chambers fell within the 3–17 range. Additionally, to analyze the response curves more precisely, the samples were divided into three groups based on the initial inoculation count: 3–17, 5–15, and 7–13. The analysis revealed no significant differences in response to the six TKIs across all groups, indicating that the data is sufficiently representative of an average of 10 cells per chamber for each group. In Fig. 5B, when the fold increase of line #1 (control) is set to 1, all response curves show a decreasing pattern as the drug concentration increases. At the peak concentration (line #9), the relative cell count decreases to 0.1 or less. The effects of six TKIs on the K562 cell line are well known, and in this study, the peak concentration of each drug (line #9) is set to approximately twice the IC50 value. Therefore, it can be confirmed that within the tested concentration range, the IC50 value is mainly determined around lines #3 to #5.
[0155] Microfluidic devices enable high-throughput single-cell level compartmentalization, which allows for the analysis of the effect of the initial cell seeding number on drug response, a factor often overlooked in conventional experiments. To investigate this more closely, relative cell response curves for six TKIs were analyzed and compared by dividing the initial seeding numbers into 0-5, 5-10, 10-15, 15-20, and 20-25 (Fig. 18). A representative histogram showing the cell distribution in 900 chambers, color-coded by initial seeding density, is presented in Fig. 19. While most response curves showed consistent drug response patterns, some deviations were observed in chambers with an initial cell count of less than 5 (< 5) or greater than 20 (> 20). As shown in Figure 17, growth inhibition is more pronounced in chambers with a high initial cell count (> 20), which may be due to the potential formation of necrotic cores within cell clusters. Conversely, chambers containing fewer than 5 cells exhibit greater variability compared to other curves, which is attributed to the difficulty in ensuring representativeness due to the small sample size. Indeed, chambers containing fewer than 5 cells account for only 17.1% of the total 900 chambers, demonstrating limitations in reflecting the average drug response. These results highlight the need for high-throughput screening for monitoring at the single-cell level and suggest that small sample sizes cannot adequately reflect overall trends.Among the six TKIs, nilotinib and bosutinib showed relatively larger variation in response depending on the initial cell number, which may be because these two drugs exhibit relatively lower efficacy than dasatinib among second-generation TKIs. In fact, dasatinib is known to have a stronger inhibitory effect and a broader range of action, and it is possible that these differences were reflected in the experiment.
[0156] 3.5. Quantification and Analysis of Drug Sensitivity Scores
[0157] Based on the response curve in Fig. 5B, we define the IC50 value for each TKI by analyzing the relative number of cells at various drug concentrations. However, IC50 values can vary depending on experimental conditions and methodologies, and evaluating drug sensitivity based solely on this value is controversial. In fact, developing robust and standardized drug sensitivity analysis indices that can ensure consistent results across laboratories remains a challenging task. To address this, we utilize various drug sensitivity indices capable of multi-faceted analysis of concentration-response data for six different drugs. These indices include: IC50 and Emax: Derived based on the dose-response curve (Fig. 6A); GR50: Calculated using a normalized growth rate curve (Fig. 6B); and DSS (Drug Sensitivity Score): A value normalized by fitting the area under relative inhibition data to a 4-parameter logistic (4PL) curve (Fig. 6C). In this process, the Hill coefficient is also derived, which represents the steepness of the dose-response relationship. The "Quest Graph™ 4PL Curve Calculator" (AAT Bioquest, Inc.) is used for 4PL curve fitting. These indicators are calculated based on drug response data obtained from chambers with an initial cell count of 3 to 17.
[0158] Figure 6D is a graph summarizing the drug sensitivity analysis results of six TKIs on the K562 cell line using five indicators: IC50, GR50, Emax, DSS, and |Hill coefficient|. The IC50 values show a trend similar to existing literature (Table S1), with slight variations due to differences in experimental conditions and initial cell numbers. In particular, the difference between an environment similar to a microfluidic-based chemostat and a conventional static culture environment may have acted as a major factor influencing the IC50 values. The IC50 values measured for the K562 cell line in a microfluidic environment were 202.5 nM for imatinib, 43.1 nM for nilotinib, 34.0 nM for bosutinib, 0.36 nM for dasatinib, 0.033 nM for ponatinib, and 7.53 nM for asimibinib. The GR50 value represents the concentration that inhibits cell growth rate by 50% and is known as a reliable indicator, particularly for cells in the exponential growth phase. Analysis results show that the GR50 values exhibit a similar trend to the IC50 values derived based on the normalized number of cells, with imatinib at 225.9 nM, nilotinib at 43.4 nM, bosutinib at 35.3 nM, dasatinib at 0.38 nM, ponatinib at 0.031 nM, and asimininib at 8.8 nM, respectively. While all six TKIs act effectively in K562 cells, there is a possibility that drug efficacy may vary depending on the cell type. In particular, differences may be more pronounced in cells with specific mutations. Analysis of the GR curves in Figure 20 confirms the reliability of the experimental results, as all TKIs effectively induce apoptosis in K562 cells at high concentrations. On the other hand, in the Ba / F3 cell line, asimininib exhibits a potent effect and induces apoptosis within the concentration range used in K562, whereas ponatinib shows moderate efficacy and leads to cell growth arrest.The effects of imatinib, nilotinib, bosutinib, and dasatinib are limited and appear to induce only partial growth inhibition. In particular, in Ba / F3 cell lines with the T315I mutation, ponatinib shows lower efficacy than in K562 cells and is found to fail to completely inhibit cell proliferation at the same concentration. On the other hand, only asimibin is identified as a drug capable of inducing a sufficient apoptotic effect. These results suggest that comparing various drug sensitivity indicators together can provide important insights into identifying the most suitable drugs for personalized therapy.
[0159] To more comprehensively evaluate analytical indicators other than IC50, radar charts representing GR50, Emax, DSS, and Hill coefficients were generated and are presented in Figures 6E-6G. This aims to provide a visual guide for personalized drug selection. The analysis results show that ponatinib exhibits particularly high efficacy in the K562 cell line across all indicators, a trend consistent with existing literature. Specifically, it demonstrates a strong inhibitory effect with low IC50 (GR50) values, followed by dasatinib. In the Ba / F3 cell line, ponatinib remains effective in terms of IC50 (GR50) and Emax values, but asimibinib has the highest DSS1 value. In both cell lines, the efficacy of imatinib and nilotinib is relatively low, which is reflected in high IC50 and GR50 values and low DSS values. In particular, for nilotinib, the slope of the inhibition curve appears steep, indicating high sensitivity to changes in drug concentration near IC50. In the case of Ba / F3 cell lines expressing the T315I mutation, imatinib, nilotinib, bosutinib, and dasatinib failed to inhibit cell growth within the drug concentration range of the K562 cell line established in the experiment; consequently, sensitivity indicators for these drugs were not calculated. On the other hand, ponatinib and asiminib were the only drugs that demonstrated efficacy against this mutation, and asiminib, in particular, was found to have higher DSS values within the concentration range established in the experiment. In contrast, ponatinib demonstrates that a relatively higher concentration is required to effectively inhibit the T315I mutation.
[0160] The study results are consistent with existing literature and confirm that dasatinib is recognized as a highly effective second-generation TKI in the K562 cell line. Ponatinib, a third-generation TKI, is known to exhibit potent activity against not only BCR-ABL1 but also various mutations resistant to existing TKIs, particularly the BCR-ABL1 T315I mutation, which is resistant to all existing TKIs. Furthermore, asimibinib, a fourth-generation TKI, is confirmed to demonstrate high efficacy in Ba / F3 cell lines harboring the T315I mutation. The highly quantitative single-cell-level drug screening device developed in this study features an automated microfluidic-based drug delivery system, which can significantly improve the reliability and reproducibility of various drug susceptibility assessment indices. Moreover, this platform enables the evaluation and ranking of drug efficacy for personalized treatment and is expected to play a crucial role in identifying the most suitable drug or drug combination for CML patients within a short period (within days).
[0161] The microfluidic device is integrated with an automated, programmable pneumatic pressure control system, opening up new possibilities for studying patient-specific drug selectivity. This system is expected to contribute to improving future therapeutic effects by enabling the experimentation of various drug combinations and the adjustment of optimal drug administration timing. In particular, the approach developed in this study holds high potential for precision therapy for patients with chronic myeloid leukemia (CML) and provides the capability to monitor cellular responses of suspended cells at the single-cell level with unprecedented resolution. Furthermore, it allows for the exploration of cellular heterogeneity, real-time analysis of dynamic cell states, and expands the possibilities for cell recovery within the chamber by combining it with advanced single-cell sequencing and proteomics technologies. Another strength of our system is its high versatility, and to further enhance this, we plan to modify the device to enable spheroid culture. By adjusting the geometrical dimensions of the microfluidic device, we intend to develop it to efficiently generate high-throughput spheroids from captured cells.
[0162] These capabilities provide complementary tools for studying cell-cell interactions and the influence of the microenvironment, ultimately paving the way for more accurate modeling of the bone marrow niche. Through this, it is expected to provide important insights that can support future human clinical trials.
[0163] 4. Conclusion
[0164] By developing a microfluidic cell culture array device and automated image processing algorithms capable of analyzing drug-cell interactions at the single-cell level, the process of selecting the optimal anticancer drug from multiple candidates is enhanced. The microfluidic device utilizes a Christmas tree-shaped mixer to generate nine levels of drug concentration, and then compartmentalizes cells into 900 culture chambers using controlled centrifugal force. Additionally, a proprietary pneumatic pressure control system is designed to enable parallel analysis by allowing the individual delivery of eight different nutrients and drugs. The image processing algorithm reliably distinguishes between living and dead cells within the culture chambers, enabling accurate counting of the number of viable cells over time. Based on this, we utilize a microfluidic cell culture array to perform comparative analyses at various TKI concentrations against six BCR-ABL1 tyrosine kinase inhibitors (TKIs)—namely imatinib, nilotinib, bosotinib, ponatinib, dasatinib, and asiminib—using K562, Ba / F3 BCR-ABL1, and Ba / F3 BCR-ABL1 cell lines expressing the T315I mutation. Our approach allows for the precise counting of viable cells at the single-cell level by maintaining an environment similar to a continuous chemostat while considering the initial cell population size, thereby enabling the derivation of drug efficacy indicators such as IC50, GR50, and DSS with high accuracy. This represents a significant improvement overcoming the limitations of conventional batch conditions, where initial inoculation density restricts cell growth. Based on mathematical analysis, the relative efficacy of anticancer drugs in K562 and Ba / F3 BCR-ABL1 cell lines was ranked from highest to lowest, with the order being ponatinib, asiminib, dasatinib, bosutinib, imatinib, and nilotinib. Ponatinib showed the highest efficacy in both cell lines, while nilotinib showed the relatively lowest efficacy and exhibited significant variability depending on the concentration.In Ba / F3 BCR-ABL1 cell lines carrying the T315I mutation, only ponatinib and asiminib were identified as effective drugs; in particular, asiminib demonstrated potent efficacy within the concentration range established in the experiment. Moving forward, we plan to apply this personalized TKI selection method to a clinical prospective study to analyze the correlation between in vitro drug sensitivity and actual patient treatment outcomes. This approach has the potential to significantly improve the precision of CML treatment and contribute to accelerating the transition toward personalized medicine.
[0165] The present invention has been described with reference to the embodiments illustrated in the drawings, but this is merely illustrative, and those skilled in the art will understand that various modifications and equivalent alternative embodiments are possible therefrom. Accordingly, the true technical scope of protection of the present invention should be determined by the technical spirit of the appended claims.
Claims
1. A microfluidic channel into which a liquid fluid is introduced and stored, in which objects having a micro or nano size are dispersed and located inside, and which has both ends closed when storage is completed; and It includes a plurality of chambers spaced apart from each other along the longitudinal direction of the microfluidic channel, communicating with the microfluidic channel, and filled with the fluid therein. When a centrifugal force acts from the microfluidic channel toward the chambers, the objects are separated and collected in the chambers by the centrifugal force. Microfluidic array.
2. In Claim 1, The microfluidic array is arranged at an angle, wherein the chambers are positioned above the microfluidic channel. Microfluidic array.
3. In Claim 1, The portion of the microfluidic channel facing each of the chambers is, A first inclined structure inclined in a direction closer to each of the chambers as it moves closer to the virtual extension lines extending from the center of each of the chambers to the microfluidic channel, along the direction in which the liquid fluid flows through the microfluidic channel; and On the opposite side of the portion where the first slope structure is formed around the aforementioned virtual extensions, the second slope structure is sloped in a direction away from each of the chambers as it moves away from the virtual extensions along the direction in which the liquid fluid flows through the microfluidic channel. Microfluidic array.
4. In Claim 3, The first slope structure and the second slope structure are formed as a symmetrical structure with respect to the virtual extension line. Microfluidic array.
5. In Claim 1, Each of the above chambers is, A plurality of chambers are spaced apart along at least one of the longitudinal direction of the microfluidic channel and the direction in which the centrifugal force acts to form a chamber group. Microfluidic array.
6. In Claim 5, A mixed fluid of the same concentration containing a drug is introduced into the chambers included in one chamber group, and a mixed fluid of different concentrations is introduced between different chamber groups. Microfluidic array.
7. In Claim 1, The above chambers are, A plurality of interconnected chamber spaces, wherein the plurality of chamber spaces are formed in a structure such that the height at which the object can pass decreases in the interconnected portion as the centrifugal force acts. Microfluidic array.
8. In Claim 7, The above chambers are, A first chamber space which is one of the above chamber spaces and has one side connected to the microfluidic channel; and A second chamber space which is one of the chamber spaces above and has one side communicating with the other side of the first chamber space. Microfluidic array.
9. In Claim 8, The vertical height of the above second chamber space is, One of the above-mentioned objects is formed to a height at which it can be placed, Microfluidic array.
10. In Claim 8, Each of the above chambers is, The second chamber space is positioned above the first chamber space. Microfluidic array.
11. A microfluidic channel into which a liquid fluid flows; and It includes a plurality of chambers spaced apart from each other along the longitudinal direction of the microfluidic channel, communicating with the microfluidic channel, and formed of a porous material that absorbs gas in part or in whole. When the liquid fluid introduced into the microfluidic channel flows into each of the chambers, the gas remaining in the chambers is pushed out by the liquid fluid and absorbed into each of the chambers, thereby filling the chambers with the liquid fluid. Microfluidic array.
12. A microfluidic array comprising: a microfluidic channel into which a liquid fluid, in which objects having a micro or nano size are dispersed and located within it, is introduced and stored, and which has both ends closed when storage is completed; and a plurality of chambers spaced apart from each other along the longitudinal direction of the microfluidic channel, communicating with the microfluidic channel, and filled with said fluid; and The above-mentioned microfluidic array is mounted thereon, and includes a rotating device that rotates the microfluidic array about a rotation axis formed in the center. When a centrifugal force acts from the microfluidic channel toward the chambers by the rotation of the microfluidic array, the objects are separated and collected in the chambers by the centrifugal force. Object capture device using a microfluidic array.
13. In Claim 12, The above-mentioned rotating device is, A base capable of rotating in place, with the rotation axis protruding vertically from the center; A holder having a central portion coupled to the rotation axis and extending radially away from the center of the base, wherein when the rotation axis rotates, the portion extending radially with the rotation axis as the central axis rotates; and A inclined plate that is coupled to a portion of the holder extending in the radial direction and is positioned at an angle relative to the holder. Object capture device using a microfluidic array.
14. In Claim 13, The above holder is, A holder body extending flatly in the above radial direction; A first guide portion having a plate shape and extending downward from one end of the holder body in a direction intersecting the radial direction; and A second guide portion having a plate shape and extending downward from the other end opposite to one end in the direction intersecting the radial direction of the holder body. Object capture device using a microfluidic array.
15. In Claim 12, The microfluidic array is arranged at an angle, wherein the chambers are positioned above the microfluidic channel. Object capture device using a microfluidic array.
16. In Claim 12, The portion of the microfluidic channel facing each of the chambers is, A first inclined structure inclined in a direction closer to each of the chambers as it moves closer to the virtual extension lines extending from the center of each of the chambers to the microfluidic channel, along the direction in which the liquid fluid flows through the microfluidic channel; and On the opposite side of the portion where the first slope structure is formed around the aforementioned virtual extensions, the second slope structure is sloped in a direction away from each of the chambers as it moves away from the virtual extensions along the direction in which the liquid fluid flows through the microfluidic channel. Object capture device using a microfluidic array.
17. In Claim 12, The above chambers are, A plurality of interconnected chamber spaces, wherein the plurality of chamber spaces are formed in a structure such that the height at which the object can pass decreases in the interconnected portion as the centrifugal force acts. Object capture device using a microfluidic array.
18. A step of preparing a microfluidic array comprising: a microfluidic channel into which a liquid fluid, in which objects having a micro or nano size are dispersed and located within, is introduced and stored, and which has both ends closed when storage is completed; and a plurality of chambers spaced apart from each other along the length direction of the microfluidic channel, communicating with the microfluidic channel, and filled with the fluid within, wherein when a centrifugal force is applied from the microfluidic channel toward the chambers, the objects are separated and captured in the chambers by the centrifugal force. A first fluid injection step of injecting a first fluid into the microfluidic channel to fill the microfluidic channel and the chambers with the first fluid; A second fluid injection step of injecting a second fluid, in which the objects are dispersed internally, into the microfluidic channel to distribute the objects in the microfluidic channel; and A target object capture step comprising causing a centrifugal force to act from the microfluidic channel toward the chambers so that the target objects flow into the chambers. Method for capturing objects using a microfluidic array.
19. In Claim 18, In the step of preparing the above microfluidic array, The above microfluidic array is formed from PDMS material, and Prior to the first fluid injection step, the method further comprises a vacuum forming step of forming a porous structure capable of absorbing air within the walls constituting the chambers by vacuum suctioning and discharging air inside the microfluidic channels of the microfluidic array and the chambers. Method for capturing objects using a microfluidic array.
20. In Claim 19, In the first fluid injection step above, When the liquid fluid introduced into the microfluidic channel flows into each of the chambers, the gas remaining in each of the chambers is pushed out by the liquid fluid and absorbed into each of the chambers, thereby completely filling each of the chambers with the first fluid. Method for capturing objects using a microfluidic array.
21. A step of preparing a microfluid array comprising: a microfluid channel into which a liquid fluid, in which objects having a micro or nano size are dispersed and located within, is introduced and stored, and which has both ends closed when storage is completed; and a plurality of chambers spaced apart from each other along the length direction of the microfluid channel, communicating with the microfluid channel, and filled with the fluid within, wherein when a centrifugal force is applied from the microfluid channel toward the chambers, the objects are separated and captured in the chambers by the centrifugal force. A first fluid injection step of injecting a first fluid into the microfluidic channel to fill the microfluidic channel and the chambers with the first fluid; A second fluid injection step of injecting a second fluid containing the above objects into the microfluidic channel to distribute the objects in the microfluidic channel; A target object capture step of causing a centrifugal force to act from the microfluidic channel toward the chambers so that the target objects flow into the chambers; A drug concentration combination step of introducing different fluids into the microfluidic array, wherein at least one of the different fluids is a drug that reacts with the target object, and forming mixed fluids mixed at different mixing ratios; and A test step comprising confirming the drug responsiveness of the object by measuring the change when the object reacts with the mixed fluids, Method for verifying drug response of a target using a microfluidic array.
22. In Claim 21, Prior to the above drug concentration combination step, In order to remove objects remaining in the microfluidic channel and keep the microfluidic channel clean, a third fluid is injected into the microfluidic channel. includes additional steps, Method for verifying drug response of a target using a microfluidic array.
23. In Claim 21, In the second fluid injection step above, In order to visually confirm the drug reactivity of the above-mentioned object, a second fluid in which an object containing a fluorescent protein that changes according to the type and concentration of the drug is dispersed is injected into the microfluidic channel. Method for verifying drug response of a target using a microfluidic array.
24. In Claim 21, In the step of preparing the above-mentioned microfluidic device, A microfluidic array is prepared in which each of the chamber groups comprises a plurality of chambers, and a fluid of the same concentration containing a drug is introduced into the plurality of chambers included in each of the chamber groups, while a fluid of a different concentration containing a drug is introduced between different chamber groups. In the above test step, Confirming the reactivity of the object according to the concentration of the drug using the number of times the object reacted to the drug in the chambers included in each of the chamber groups above. Method for verifying drug response of an object using a microfluidic device.
